Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D HellmannTudor-Eliade CiuleanuAdam PluzanskiJong Seok LeeGregory A OttersonClarisse Audigier-ValetteElisa MinenzaHelena LinardouSjaak BurgersPamela SalmanHossein BorghaeiSuresh S RamalingamJulie BrahmerMartin ReckKenneth J O'ByrneWilliam J GeeseGeorge GreenHan ChangJoseph SzustakowskiPrabhu BhagavatheeswaranDiane HealeyYali FuFaith NathanLuis Paz-AresPublished in: The New England journal of medicine (2018)
Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden, irrespective of PD-L1 expression level. The results validate the benefit of nivolumab plus ipilimumab in NSCLC and the role of tumor mutational burden as a biomarker for patient selection. (Funded by Bristol-Myers Squibb and Ono Pharmaceut